E-LIB Suche - Ergebnisse für: Jurczak, W

1

Characterization of Mechanisms of Resistance in Previously ..:

Woyach, J. A. ; Jones, D. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 249-250 , 2023

Link: https://doi.org/10.1002/..

2

Safety and Efficacy of Acalabrutinib, Bendamustine, and Rit..:

Phillips, T. ; Wang, M. ; Robak, T....
Hematological Oncology. 41 (2023) S2 - p. 586-587 , 2023

Link: https://doi.org/10.1002/..

3

COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEI..:

Jurczak, W. ; Lamanna, N. ; Tam, C. S....
Hematological Oncology. 41 (2023) S2 - p. 758-759 , 2023

Link: https://doi.org/10.1002/..

4

Zanubrutinib safety/tolerability profile and comparison wit..:

Brown, J. R. ; Eichorst, B. ; Ghia, P....
Hematological Oncology. 41 (2023) S2 - p. 459-461 , 2023

Link: https://doi.org/10.1002/..

5

CC‐99282 plus R‐CHOP in patients (pts) with previously untr..:

Munoz, J. ; Hoffmann, M. ; Westin, J....
Hematological Oncology. 41 (2023) S2 - p. 584-586 , 2023

Link: https://doi.org/10.1002/..

6

PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN P..:

Danilov, A. ; Gregory, G. P. ; Morschhauser, F....
Hematological Oncology. 41 (2023) S2 - p. 129-131 , 2023

Link: https://doi.org/10.1002/..

7

SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REM..:

Thieblemont, C. ; Karimi, Y. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 142-144 , 2023

Link: https://doi.org/10.1002/..

8

Long‐term safety with ≥12 months of pirtobrutinib in relaps..:

Wang, Y. ; Coombs, C. C. ; Shah, N. N....
Hematological Oncology. 41 (2023) S2 - p. 480-481 , 2023

Link: https://doi.org/10.1002/..

9

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALE..:

Brown, JR ; Woyach, JA ; Patel, K...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S160-S161 , 2023

Link: https://doi.org/10.1016/..

10

A phase 2 study of zilovertamab vedotin as monotherapy or i..:

Zinzani, P. L. ; Mayer, J. ; Benjamini, O....
Hematological Oncology. 41 (2023) S2 - p. 564-565 , 2023

Link: https://doi.org/10.1002/..

11

Five‐year subgroup analysis of tafasitamab + lenalidomide f..:

Duell, J. ; Abrisqueta, P. ; Dreyling, M....
Hematological Oncology. 41 (2023) S2 - p. 439-441 , 2023

Link: https://doi.org/10.1002/..

12

Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in r..:

McDonald, A. ; Verburgh, E. ; Gotti, M....
Hematological Oncology. 41 (2023) S2 - p. 575-577 , 2023

Link: https://doi.org/10.1002/..

13

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazin..:

Abramson, J. S. ; Straus, D. ; Bartlett, N....
Hematological Oncology. 41 (2023) S2 - p. 353-355 , 2023

Link: https://doi.org/10.1002/..

14

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:

Cheah, C. Y. ; Shah, N. N. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 153-156 , 2023

Link: https://doi.org/10.1002/..

15

COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEI..:

Lamanna, N ; Tam, CS ; Jurczak, W...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S161 , 2023

Link: https://doi.org/10.1016/..